Open an account

Aprea Therapeutics

APRE · NASDAQ

$0.5612+$0.0289 (+5.43%)TodayMarket closed ·
Prev close $0.5323

About APRE

Aprea Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the provision of cancer therapeutics. The company is headquartered in Doylestown, Pennsylvania and currently employs 8 full-time employees. The company went IPO on 2019-10-03. The Company’s pipeline includes two clinical-stage synthetic lethality programs. Its lead programs are APR-1051, an oral, small-molecule inhibitor of WEE1 kinase, and ATRN-119, a small-molecule ATR inhibitor, both in clinical development for solid tumor indications. Its ATRN-119 is an oral small molecule inhibitor of ataxia telangiectasia and Rad3-related (ATR). The ATR kinase is a master regulator of Deoxyribonucleic Acid (DNA) damage response, with roles in cell cycle control and DNA repair following replication stress. The company is evaluating potential combination opportunities within its pipeline, including research on the combination of ATRN-119 and APR-1051 that is supported by a Phase II SBIR grant from the National Cancer Institute. The company also has an early-stage program, in the lead optimization stage, for an undisclosed DNA-damage response (DDR) target.

Employees
8
Headquarters
Doylestown, Pennsylvania
Listed
Oct 3, 2019
Sector
Health Care
Industry
Biotechnology
Website
aprea.com

APRE key statistics

Market cap
7.07M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
264.37K
Volume
339.82K
Open price
$0.545
High today
$0.5674
Low today
$0.5106
52 Week high
$1.69
52 Week low
$0.5296

Aprea Therapeutics (APRE) at a glance

As of Oct 20, 2026, Aprea Therapeutics (APRE) shares are priced at $0.5612, giving the company a market cap of 7.07M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $0.5106 and $0.5674. The current price is 9.9% above the day's low and 1.1% below its high.

Volume so far is 339.82K shares, above the average of 264.37K shares a day.

Over the past year Aprea Therapeutics has ranged from $0.5296 to $1.69, and now sits 3% of the way up that range.

Aprea Therapeutics met or beat analyst EPS estimates in 7 of the last 8 quarters. In Q2 FY26 it reported -$0.07 per share against an estimate of -$0.2397.

The average analyst price target is $3.81, 578.5% above the current price, from 4 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 4 analyst ratings say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 5 analystsAvg $3.81
Low
$1.21
Now
$0.5612
High
$5.25

APRE earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 7 of the last 8 quarters, by 26.2% on average.

  1. Q2 FY24: reported -$0.58 per share against an estimate of -$0.6477
  2. Q3 FY24: reported -$0.64 per share against an estimate of -$0.7599
  3. Q4 FY24: reported -$0.49 per share against an estimate of -$0.7004
  4. Q2 FY25: reported -$0.53 per share against an estimate of -$0.7599
  5. Q3 FY25: reported -$0.47 per share against an estimate of -$0.3453
  6. Q4 FY25: reported -$0.32 per share against an estimate of -$0.3978
  7. Q1 FY26: reported -$0.22 per share against an estimate of -$0.2346
  8. Q2 FY26: reported -$0.07 per share against an estimate of -$0.2397

APRE news

  • 12 Health Care Stocks Moving In Thursday's Intraday Session

  • 12 Health Care Stocks Moving In Monday's Intraday Session

  • Press releasePRNewswire

    Lipocine Appoints Michael J. Grissinger to Board of Directors

  • Press releaseGlobe Newswire

    Next-Generation DNA Repair Therapies Open New Frontiers in Oncology

  • Press releaseBusiness Wire

    CatalYm Appoints Christian S. Schade as Chairman of the Board of Directors

  • Press releaseBusiness Wire

    Frazier Life Sciences Appoints Christian Schade as Senior Advisor

  • 12 Health Care Stocks Moving In Monday's Pre-Market Session

  • 12 Health Care Stocks Moving In Friday's Pre-Market Session

Similar companies

Companies in the same industry as Aprea Therapeutics

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.